Yale School of Medicine

“We now have convincing evidence that these tests help identify more sites of prostate cancer," said Michael Leapman, MD.

"We increasingly see the evolving role of ‘precision medicine’ in urology, using genetic and genomic testing to guide [management] for a variety of diseases, particularly bladder and prostate cancer," says 1 urologist.

A Yale chemist and oncologist collaborated to create a new treatment for prostate cancer that tags specific proteins within the cancerous cells, making it easier for the body’s natural mechanisms to identify and destroy them.

"I have no doubt we’ll become a destination program. We have a great team. Combined with a few key recruitments, we will be set to take our place on the global stage of urology," says Isaac Y. Kim, MD, PhD, MBA, urology professor and chair, Yale Urology.

"It’s the most satisfying of all the things I do as a surgeon. The benefits are so dramatic and often immediate," said Daniel Kellner, MD.

Yale Urology has ranked among the top 50 urology programs in the nation and #1 in Connecticut in U.S. News & World Report’s just-released listing.

“We found that Medicaid acceptance differed widely across cancer care facilities," said Michael Leapman, MD, MHS, associate professor of Urology, clinical program leader for the Prostate & Urologic Cancers Program at Yale Cancer Center and Smilow Cancer Hospital.

Smilow Cancer Hospital offers the latest treatments for prostate cancer, including single-port robotic radical prostatectomy.

Proteolysis-targeting chimaera, or PROTACs, work by using elements of the body’s natural protein recycling system and recruiting them toward cancerous proteins

"Because testicular cancer is most often diagnosed in young men and treatments are very successful, the focus is on minimizing the short- and long-term impacts of treatment," says Sprenkle.

Preventable factors account for a large part of the formation of tumors of the bladder and skin.

In discussing treatment determinations, Petrylak noted that for patients with low PD-L1 expression had decreased survival benefits compared with patients treated with chemotherapy in the monotherapy arms of the phase 3 KEYNOTE-361 (NCT02853305) and phase 3 IMVIGOR-130 (NCT02807636) trials.

“There are many trials that clinicians should be aware of,” says Daniel P. Petrylak, MD.

“One of the reasons I so enjoy this conference is the multidisciplinary nature,” says Peter A. Humphrey, MD, PhD.

“This first disclosure of data supports the ongoing phase 2 and 3 programs evaluating enfor-tumab vedotin alone or in combination with pembrolizumab in MIBC,” said Daniel P. Petrylak, MD.

"These findings underscore the importance of screening guidelines from the task force and the rapid responsiveness of clinicians and patients,” said Michael S. Leapman, MD.

A recent study sought to investigate the trends in sudden and significant private equity acquisitions among urology practices between 2011 and 2021.

There was limited clinical activity with the combination in patients with HRD-negative tumors.

The SAP program cultivates a community of advocacy groups, medical associations, and medical institutions to foster collaboration and an open exchange of information among trusted peers for the ultimate benefit of patients and their families.

Michael E. Hurwitz, MD, PhD, discusses how immune checkpoint inhibitors have transformed the first-line setting in advanced renal cell carcinoma.

The decline in total testosterone was observed even among men with normal body mass index.

Pembrolizumab has been granted a second tumor-agnostic FDA indication, this one for patients with solid tumors with a high tumor mutational burden.

Neither oral nor gel testosterones show significant effect on liver function test results.

Prostatic artery embolization offers a safe and durably effective treatment for urinary retention and gross hematuria in challenging non-index BPH patients, according to the results of a retrospective study published in Urology (Nov. 14, 2019 [Epub ahead of print]).

Patients with ureteral stents are rarely lost to follow-up, but the risk is increased when patients are stented in an emergent setting rather than as part of an elective procedure, Yale University urologists reported at the 2018 World Congress of Endourology in Paris.